Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: Emerging significance of image segmentation and global disease assessment

Molecular Imaging and Biology

Volumn 13, Issue 5, 2011, Pages 801-811

  Basu, Sandip ^a   Saboury, Babak ^b   Torigian, Drew A ^b   Alavi, Abass ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

FDG; Malignant pleural mesothelioma; Mesothelioma; PET; PET CT; Pleural mesothelioma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE SEGMENTATION; OUTCOME ASSESSMENT; PLEURA DISEASE; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIATION RESPONSE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH;

EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84855653918     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0426-6     Document Type: Review

References (54)

1. Antman KH (1993) Natural history and epidemiology of malignant mesothelioma. Chest 103(4 Suppl):373S-376S (Pubitemid 23110357)
2. Pisani RJ, Colby TV, Williams DE (1988) Malignant mesothelioma of the pleura. Mayo Clin Proc 63(12):1234-1244 (Pubitemid 19022523)
3. Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666-672 (Pubitemid 29046253)
4. Vogelzang NJ (2005) Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 50(Suppl 1):S23-S24 (Pubitemid 41618296)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644 (Pubitemid 46606305)
6. O'Brien ME, Watkins D, Ryan C et al (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: The MED trial. Ann Oncol 17:270-275 (Pubitemid 43160117)
7. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S (2009) Clinical value of fluorodeoxyglucose-positron emission tomography/ computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: An observational pilot study. J Thorac Oncol 4(12):1480-1484
8. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, Kutlu CA (2009) The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg 57(4):217-221, Epub 2009 May 20
9. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122-1128
10. Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 117:54-63, discussion 63-55
11. Leung AN, Muller NL, Miller RR (1990) CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 154:487-492 (Pubitemid 20071594)
12. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C (1999) Staging of malignant pleural mesothelioma: Comparison of CT and MR imaging. AJR Am J Roentgenol 172(4):1039-1047 (Pubitemid 29505636)
13. Marom EM, Erasmus JJ, Pass HI, Patz EF Jr (2002) The role of imaging in malignant pleural mesothelioma. Semin Oncol 29(1):26-35 (Pubitemid 34163532)
14. Armato SG 3rd, Entwisle J, Truong MT et al (2008) Current state and future directions of pleural mesothelioma imaging. Lung Cancer 59:411-420 (Pubitemid 351335110)
15. Wang ZJ, Reddy GP, Gotway MB et al (2004) Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET. Radiographics 24:105-119 (Pubitemid 38134597)
16. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, Caputo G, Jablons D (2000) Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120 (1):128-133 (Pubitemid 30471221)
17. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW (2003) Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 126(1):11-16 (Pubitemid 36909936)
18. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3):713-722 (Pubitemid 28433730)
19. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, Treves ST (2003) Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax 58(12):1077-1082 (Pubitemid 37542115)
20. Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC (2003) Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44:24-29 (Pubitemid 36077708)
21. Cohade C, Osman M, Marshall LN, Wahl RN (2003) PET-CT: Accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging 30:721-726 (Pubitemid 36612955)
22. Lardinois D, Weder W, Hany TF et al (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507 (Pubitemid 36706537)
23. von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: Current applications and future directions. Radiology 238:405-422 (Pubitemid 43134354)
24. Erasmus JJ, Truong MT, Smythe WR et al (2005) Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 129:1364-1370 (Pubitemid 40804856)
25. Plathow C, Staab A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, Peter SH, Eschmann S, Klopp M (2008) Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging oflimited pleural mesothelioma: Initial results. Invest Radiol 43 (10):737-744
26. Sorensen JB, Ravn J, Loft A, Brenøe J, Berthelsen AK (2008) Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emissiontomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg 34(5):1090-1096, Epub 2008 Sep 16
27. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols FC III, Aubry MC, Jett JR (2009) Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 10 (4):244-248
28. Ambrosini V, Rubello D, Nanni C, Farsad M, Castellucci P, Franchi R, Fabbri M, Rampin L, Crepaldi G, Al-Nahhas A, Fanti S (2005) Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alonein the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur 8(2):111-115 (Pubitemid 43115961)
29. Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L (2010) Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol 5(3):385-388
30. Hicks RJ, Mac Manus MP, Matthews JP et al (2004) Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60:412-418 (Pubitemid 39233459)
31. Berriolo-Riedinger A, Touzery C, Riedinger JM et al (2007) [(18)F] FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34:1915-1924 (Pubitemid 350212117)
32. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response inmalignant pleural mesothelioma. Ann Oncol 15(2):257-260 (Pubitemid 38262625)
33. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA (2010) Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 67(3):311-317, Epub 2009 May 30
34. Ceresoli GL, Chiti A, Zucali PA et al (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24:4587-4593 (Pubitemid 46630956)
35. Chang CL, Wu TC, Hung CF (2007) Control of human mesothelinexpressing tumors by DNA vaccines. Gene Ther 14:1189-1198
36. Francis RJ, Byrne MJ, van der Schaaf AA et al (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volumebased analysis of serial 18F-FDG PET scans. J Nucl Med 48:1449-1458 (Pubitemid 47397395)
37. Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, MitchellP KSR, Feigen M, Scott AM (2009) Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol 11(6):473-479
38. Krüger S, Pauls S, Mottaghy FM, Buck AK, Schelzig H, Hombach V, Reske SN (2007) Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma. Nuklearmedizin 46(6):239-243 (Pubitemid 350293568)
39. Pehlivan B, Topkan E, Onal C, Nursal GN, Yuksel O, Dolek Y, Yavuz MN, Yavuz AA (2009) Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma. Radiat Oncol 4:35
40. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B (2006) Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52:189-197
41. Vachani A, Sterman DH, Albelda SM (2007) Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2:265-267 (Pubitemid 47181706)
42. Sterman DH, Recio A, Carroll RG et al (2007) A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: High rate of antitumor immune responses. Clin Cancer Res 13:4456-4466 (Pubitemid 47219714)
43. Mankoff DA, Shields AF, Krohn KA (2005) PET imaging of cellular proliferation. Radiol Clin North Am 43:153-167 (Pubitemid 40326566)
44. Lucignani G (2008) PET imaging with hypoxia tracers: A must in radiation therapy. Eur J Nucl Med Mol Imaging 35(4):838-842
45. Basu S, Alavi A (2009) Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am 19(4):625-646
46. Tsuji AB, Sogawa C, Sugyo A, Sudo H, Toyohara J, Koizumi M, Abe M, Hino O, Harada YN, Furukawa T, Suzuki K, Saga T (2009) Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl Med Biol 36(4):379-388
47. Alavi A, Newberg AB, Souder E, Berlin JA (1993) Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 34 (10):1681-1687 (Pubitemid 23295377)
48. Bural GG, Torigian DA, Chamroonrat W, Alkhawaldeh K, Houseni M, El-Haddad G, Alavi A (2006) Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: A new concept. Nucl Med Biol 33(8):1037-1043 (Pubitemid 44791952)
49. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A (2008) Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: A novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 29 (6):521-526 (Pubitemid 351643419)
50. Bural GG, Torigian DA, Burke A, Houseni M, Alkhawaldeh K, Cucchiara A, Basu S, Alavi A (2010) Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: A novel concept. Mol Imaging Biol 12(3):233-239
51. BasuS,Zaidi H, HouseniM, BuralG, Udupa J, Acton P, Torigian DA, Alavi A (2007) Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: Implications for normal variation, aging and diseased states. Semin Nucl Med 37(3):223-239 (Pubitemid 46533824)
52. Hofheinz F, Pötzsch C, van den Hoff J (2007) Quantxtative 3D ROI delineation in PET: Algorithm and validation. J Nucl Med 48:407P
53. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241-1245 (Pubitemid 29385629)
54. Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A (2009) XPotential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol 11(5):369-378, Epub 2009 May 27